Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:35 a.m. Eastern Time.
The presentation will be accessible via live webcast through the Investors section of Kiniksa's website at www.kiniksa.com. A replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was +1.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.